-
FMC Eases Some Publication Requirements For Ocean Container Carriers
Thursday, June 11, 2020 - 4:14pm | 504Read More...The U.S. Federal Maritime Commission (FMC) on Thursday adopted a final rule that eases certain publication requirements for ocean container carriers, providing partial relief sought by the World Shipping Council in a 2018 petition to the agency. The FMC's approval of the rule follows a Feb. 14...
-
Exclusive: Following Up Akebia, Johnson & Johnson's Research And License Agreement
Friday, February 17, 2017 - 11:21am | 909Read More...On Monday, Akebia Therapeutics Inc (NASDAQ: AKBA) signed a $1 million research and license agreement with Johnson & Johnson (NYSE: JNJ) to access hundreds of hypoxia inducible factor (HIF)-targeted compounds. This access includes a coveted preclinical candidate for inflammatory bowel disease (...
-
Akebia Therapeutics Lower Following Announcement Of Public Offering, Corporate And Clinical Developments
Tuesday, January 5, 2016 - 10:03am | 297Read More...Shares of Akebia Therapeutics Inc (NASDAQ: AKBA), a biopharmaceutical company that focuses on products for the treatment of kidney diseases, were trading lower by around 0.5 percent early Tuesday morning after the company announced it plans on offering and selling $75 million worth of its...
-
EXCLUSIVE: Akebia CEO On Huge New Partnership Deal
Monday, December 14, 2015 - 2:38pm | 522Read More...Akebia Therapeutics Inc (NASDAQ: AKBA) has announced a partnership with Mitsubishi Tanabe Pharma on development of vadadustat. The deal could be worth up to $350 million for Akebia. Akebia CEO John Butler told Benzinga that the company is pleased with both the terms of the deal and the partner....
